The Genetic Basis, Lung Involvement, and Therapeutic Options in Niemann–Pick Disease: A Comprehensive Review
Biomolecules · 11.02.2024 · 14 (2) · 211
DOI: 10.3390/biom14020211 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 11.02.2024. Verfasst von Claudio Tirelli und 10 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Unit, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, 20142 Milan, Italy. Hauptthemen laut MEDLINE: Niemann-Pick Disease, Type A, Niemann-Pick Disease, Type B, Niemann-Pick Diseases, Lung Diseases. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Niemann–Pick Disease (NPD) is a rare autosomal recessive disease belonging to lysosomal storage disorders. Three types of NPD have been described: NPD type A, B, and C. NPD type A and B are caused by mutations in the gene SMPD1 coding for sphingomyelin phosphodiesterase 1, with a consequent lack of acid sphingomyelinase activity. These diseases have been thus classified as acid sphingomyelinase deficiencies (ASMDs). NPD type C is a neurologic disorder due to mutations in the genes NPC1 or NPC2, causing a defect of cholesterol trafficking and esterification. Although all three types of NPD can manifest with pulmonary involvement, lung disease occurs more frequently in NPD type B, typically with interstitial lung disease, recurrent pulmonary infections, and respiratory failure. In this sense, bronchoscopy with broncho-alveolar lavage or biopsy together with high-resolution computed tomography are fundamental diagnostic tools. Although several efforts have been made to find an effective therapy for NPD, to date, only limited therapeutic options are available. Enzyme replacement therapy with Olipudase α is the first and only approved disease-modifying therapy for patients with ASMD. A lung transplant and hematopoietic stem cell transplantation are also described for ASMD in the literature. The only approved disease-modifying therapy in NPD type C is miglustat, a substrate-reduction treatment. The aim of this review was to delineate a state of the art on the genetic basis and lung involvement in NPD, focusing on clinical manifestations, radiologic and histopathologic characteristics of the disease, and available therapeutic options, with a gaze on future therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Respiratory Unit, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, 20142 Milan, Italy.
- Medical Genetics Unit, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, 20142 Milan, Italy.
ORCID-Profile: Claudio Tirelli, Ornella Rondinone, Gabriele Guido
Zitieren
APA
Tirelli, C., Rondinone, O., Italia, M., Mira, S., Belmonte, L. A., De Grassi, M., Guido, G., Maggioni, S., Mondoni, M., Miozzo, M. R., & Centanni, S. (2024). The Genetic Basis, Lung Involvement, and Therapeutic Options in Niemann–Pick Disease: A Comprehensive Review. Biomolecules, 14(2), 211. https://doi.org/10.3390/biom14020211
Vancouver
Tirelli C, Rondinone O, Italia M, Mira S, Belmonte LA, De Grassi M, et al. The Genetic Basis, Lung Involvement, and Therapeutic Options in Niemann–Pick Disease: A Comprehensive Review. Biomolecules. 2024;14(2):211. doi:10.3390/biom14020211
BibTeX
@article{Tirelli2024,
author = {Tirelli, Claudio and Rondinone, Ornella and Italia, Marta and Mira, Sabrina and Belmonte, Luca Alessandro and De Grassi, Mauro and Guido, Gabriele and Maggioni, Sara and Mondoni, Michele and Miozzo, Monica Rosa and Centanni, Stefano},
title = {The Genetic Basis, Lung Involvement, and Therapeutic Options in Niemann–Pick Disease: A Comprehensive Review},
journal = {Biomolecules},
year = {2024},
volume = {14},
number = {2},
pages = {211},
doi = {10.3390/biom14020211}
}
EUVIMED